Steven Cohen Graphite Bio, Inc. Transaction History

Point72 Asset Management, L.P.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$8.41 - $16.71 $42,050 - $83,550	-5,000 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$15.81 - $28.39 $79,050 - $141,950	-5,000 Reduced 50.0%	5,000 $82,000
Q2 2021 Aug 16, 2021	BUY	$18.5 - $30.73 $185,000 - $307,300	10,000 New	10,000 $307,000

637K

Ticker GRPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,211,200
Description
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expres...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.